Joints for joints: cannabinoids in the treatment of rheumatoid arthritis
Tóm tắt
An increasing number of patients with rheumatoid arthritis (RA) are using cannabis to treat their symptoms, although systematic studies regarding efficacy in RA are lacking. Within this review we will give an overview on the overall effects of cannabinoids in inflammation and why they might be useful in the treatment of RA.
Peripherally, cannabinoids show anti-inflammatory effects by activating cannabinoid type 2 receptors (CB2) which decrease cytokine production and immune cell mobilization. In contrast, cannabinoid type 1 receptor (CB1) activation on immune cells is proinflammatory while CB1 antagonism provides anti-inflammatory effects by increasing β2-adrenergic signaling in the joint and secondary lymphoid organs. In addition, the nonpsychotropic cannabinoid, cannabidiol (CBD) demonstrated antiarthritic effects independent of cannabinoid receptors. In addition to controlling inflammation, cannabinoids reduce pain by activating central and peripheral CB1, peripheral CB2 receptors and CBD-sensitive noncannabinoid receptor targets.
Cannabinoids might be a suitable treatment for RA, but it is important to target the right receptors in the right place. For clinical studies, we propose a combination of a CB2 agonist to decrease cytokine production, a peripheral CB1 antagonist to prevent detrimental CB1 signaling and to support anti-inflammatory effects of CB2 via activation of β2-adrenergic receptors and CBD to induce cannabinoid-receptor-independent anti-inflammatory effects.
Từ khóa
Tài liệu tham khảo
Pisanti, 2018, Medical cannabis: a plurimillennial history of an evergreen, J Cell Physiol
Peschel, 2015, (1)H NMR and HPLC/DAD for Cannabis sativa L. chemotype distinction, extract profiling and specification, Talanta, 140, 150, 10.1016/j.talanta.2015.02.040
Sales, 2018, Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels, Prog Neuropsychopharmacol Biol Psychiatry, 86, 255, 10.1016/j.pnpbp.2018.06.002
Laun, 2018, GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol, Acta Pharmacol Sin
Iannotti, 2014, Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability, ACS Chem Neurosci, 5, 1131, 10.1021/cn5000524
Navarro, 2018, Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1–CB2 heteroreceptor complexes, Biochem Pharmacol, 157, 148, 10.1016/j.bcp.2018.08.046
Nabissi, 2013, Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents, Carcinogenesis, 34, 48, 10.1093/carcin/bgs328
Kapur, 2009, Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands, J Biol Chem, 284, 29817, 10.1074/jbc.M109.050187
Katona, 2009, Endocannabinoid receptors: CNS localization of the CB(1) cannabinoid receptor, Curr Top Behav Neurosci, 1, 65, 10.1007/978-3-540-88955-7_3
Galiegue, 1995, Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations, Eur J Biochem, 232, 54, 10.1111/j.1432-1033.1995.tb20780.x
Grzeda, 2017, CB1 receptor activation in the rat paraventricular nucleus induces bi-directional cardiovascular effects via modification of glutamatergic and GABAergic neurotransmission, Naunyn Schmiedebergs Arch Pharmacol, 390, 25, 10.1007/s00210-016-1302-y
Mendiguren, 2018, Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects, Life Sci, 192, 115, 10.1016/j.lfs.2017.11.029
Cencioni, 2010, Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors, PLoS One, 5, e8688, 10.1371/journal.pone.0008688
Guabiraba, 2013, Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis, Inflamm Res, 62, 811, 10.1007/s00011-013-0638-8
Chiurchiu, 2013, Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis, Ann Neurol, 73, 626, 10.1002/ana.23875
Jorda, 2002, Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol, Blood, 99, 2786, 10.1182/blood.V99.8.2786
Agudelo, 2008, Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes, J Neuroimmune Pharmacol, 3, 35, 10.1007/s11481-007-9088-9
Basu, 2011, Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses, J Immunol, 187, 5720, 10.4049/jimmunol.1102195
Chan, 2017, Metabolic gatekeeper function of B-lymphoid transcription factors, Nature, 542, 479, 10.1038/nature21076
Romero, 2013, CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system, Anesth Analg, 116, 463, 10.1213/ANE.0b013e3182707859
Vogel, 1993, Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase, J Neurochem, 61, 352, 10.1111/j.1471-4159.1993.tb03576.x
Di, 1996, Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells, Biochem Biophys Res Commun, 227, 281, 10.1006/bbrc.1996.1501
Ross, 2003, Anandamide and vanilloid TRPV1 receptors, Br J Pharmacol, 140, 790, 10.1038/sj.bjp.0705467
Musella, 2017, A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum, Sci Rep, 7, 7363, 10.1038/s41598-017-07519-8
Ueda, 2000, The fatty acid amide hydrolase (FAAH), Chem Phys Lipids, 108, 107, 10.1016/S0009-3084(00)00190-0
Dinh, 2002, Brain monoglyceride lipase participating in endocannabinoid inactivation, Proc Natl Acad Sci U S A, 99, 10819, 10.1073/pnas.152334899
Urquhart, 2015, Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases, Biochim Biophys Acta, 1851, 366, 10.1016/j.bbalip.2014.12.015
Alhouayek, 2014, COX-2-derived endocannabinoid metabolites as novel inflammatory mediators, Trends Pharmacol Sci, 35, 284, 10.1016/j.tips.2014.03.001
Scarpelli, 2016, A double whammy: targeting both fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX) to treat pain and inflammation, ChemMedChem, 11, 1242, 10.1002/cmdc.201500395
Walitt, 2016, Cannabinoids for fibromyalgia, Cochrane Database Syst Rev, 7, CD011694
Katz-Talmor, 2018, Cannabinoids for the treatment of rheumatic diseases – where do we stand?, Nat Rev Rheumatol, 14, 488, 10.1038/s41584-018-0025-5
Malfait, 2000, The nonpsychoactive cannabis constituent cannabidiol is an oral antiarthritic therapeutic in murine collagen-induced arthritis, Proc Natl Acad Sci U S A, 97, 9561, 10.1073/pnas.160105897
Sofia, 1973, Antiedema and analgesic properties of delta9-tetrahydrocannabinol (THC), J Pharmacol Exp Ther, 186, 646
Sumariwalla, 2004, A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis, Arthritis Rheum, 50, 985, 10.1002/art.20050
Kinsey, 2011, Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice, Pharmacol Biochem Behav, 99, 718, 10.1016/j.pbb.2011.06.022
Marrie, 2018, Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases, Gen Hosp Psychiatry, 53, 65, 10.1016/j.genhosppsych.2018.06.001
Bartok, 2010, Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis, Immunol Rev, 233, 233, 10.1111/j.0105-2896.2009.00859.x
Dhillon, 2017, Tofacitinib: a review in rheumatoid arthritis, Drugs, 77, 1987, 10.1007/s40265-017-0835-9
Geng, 2018, Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials, Clin Exp Rheumatol
Caporali, 2018, 20 years of experience with tumour necrosis factor inhibitors: what have we learned?, Rheumatology (Oxford), 57, vii5, 10.1093/rheumatology/key059
Gaul, 1975, Delta-9-tetrahydrocannabinol and decreased macrophage migration inhibition activity, Res Commun Chem Pathol Pharmacol, 10, 559
Raz, 1976, Effect of hashish compounds on mouse peritoneal macrophages, Lab Invest, 34, 69
Persidsky, 2015, Activation of cannabinoid type two receptors (CB2) diminish inflammatory responses in macrophages and brain endothelium, J Neuroimmune Pharmacol, 10, 302, 10.1007/s11481-015-9591-3
Jiang, 2016, Selective activation of CB2 receptor improves efferocytosis in cultured macrophages, Life Sci, 161, 10, 10.1016/j.lfs.2016.07.013
Ke, 2016, Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting NLRP3 inflammasome in macrophages, PLoS One, 11, e0155076, 10.1371/journal.pone.0155076
Gui, 2015, Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis, Immunobiology, 220, 817, 10.1016/j.imbio.2014.12.012
Ismail, 2018, Study of cannabinoid receptor 2 Q63R gene polymorphism in Lebanese patients with rheumatoid arthritis, Clin Rheumatol, 37, 2933, 10.1007/s10067-018-4217-9
Lecru, 2015, Cannabinoid receptor 1 is a major mediator of renal fibrosis, Kidney Int, 88, 72, 10.1038/ki.2015.63
Ruiz, 2017, Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages, J Clin Invest, 127, 4148, 10.1172/JCI83626
Duncan, 2013, Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation, Am J Physiol Regul Integr Comp Physiol, 305, R224, 10.1152/ajpregu.00104.2013
Han, 2009, CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages, Cardiovasc Res, 84, 378, 10.1093/cvr/cvp240
Moreira, 2009, The psychiatric side-effects of rimonabant, Rev Bras Psiquiatr, 31, 145, 10.1590/S1516-44462009000200012
Silvestri, 2012, Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders, Expert Opin Investig Drugs, 21, 1309, 10.1517/13543784.2012.704019
Kozela, 2016, HU-446 and HU-465, derivatives of the nonpsychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells, Chem Biol Drug Des, 87, 143, 10.1111/cbdd.12637
Robinson, 2015, A CB2-selective cannabinoid suppresses T-cell activities and increases Tregs and IL-10, J Neuroimmune Pharmacol, 10, 318, 10.1007/s11481-015-9611-3
Kong, 2014, Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS, Cell Immunol, 287, 1, 10.1016/j.cellimm.2013.11.002
Singh, 2012, Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(−/−) mice by attenuating the activation of T cells and promoting their apoptosis, Toxicol Appl Pharmacol, 258, 256, 10.1016/j.taap.2011.11.005
Klein, 1985, The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses, J Immunopharmacol, 7, 451, 10.3109/08923978509026487
Schatz, 1993, Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function, Immunopharmacology, 26, 129, 10.1016/0162-3109(93)90005-B
Bhargava, 1996, Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol, Pharmacology, 52, 271, 10.1159/000139392
Zhu, 1998, Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1, J Pharmacol Exp Ther, 286, 1103
Dhital, 2017, Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation, Cell Immunol, 312, 25, 10.1016/j.cellimm.2016.11.006
De, 2012, Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation, Acta Physiol (Oxf), 204, 255, 10.1111/j.1748-1716.2011.02338.x
O'Sullivan, 2010, Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease, Immunobiology, 215, 611, 10.1016/j.imbio.2009.09.007
Lowin, 2015, Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner, Arthritis Res Ther, 17, 321, 10.1186/s13075-015-0845-5
Dhopeshwarkar, 2017, Two janus cannabinoids that are both CB2 agonists and CB1 antagonists, J Pharmacol Exp Ther, 360, 300, 10.1124/jpet.116.236539
Hudson, 2010, Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors, Br J Pharmacol, 160, 627, 10.1111/j.1476-5381.2010.00681.x
Mnich, 2010, Anti-inflammatory properties of CB1-receptor antagonist involves beta2 adrenoceptors, J Pharmacol Exp Ther, 333, 445, 10.1124/jpet.109.163998
Klodzinski, 2018, Comorbidities in rheumatic arthritis, Reumatologia, 56, 228, 10.5114/reum.2018.77974
Dougados, 2014, Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA), Ann Rheum Dis, 73, 62, 10.1136/annrheumdis-2013-204223
del, 2008, Disrupted brain-immune system-joint communication during experimental arthritis, Arthritis Rheum, 58, 3090, 10.1002/art.23869
Adlan, 2017, Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis, J Physiol, 595, 967, 10.1113/JP272944
Godfrey, 2018, Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis, J Psychiatr Res, 105, 33, 10.1016/j.jpsychires.2018.08.015
Pongratz, 2014, The sympathetic nervous system in inflammation, Arthritis Res Ther, 16, 504, 10.1186/s13075-014-0504-2
Fassold, 2009, Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repulsion and arthritis, Arthritis Rheum, 60, 2892, 10.1002/art.24860
Capellino, 2012, First appearance and location of catecholaminergic cells during experimental arthritis and elimination by chemical sympathectomy, Arthritis Rheum, 64, 1110, 10.1002/art.33431
Medina, 2018, Metabolic syndrome, autoimmunity and rheumatic diseases, Pharmacol Res, 133, 277, 10.1016/j.phrs.2018.01.009
Malinowska, 2018, Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance, Br J Pharmacol
Sidney, 2016, Marijuana use and type 2 diabetes mellitus: a review, Curr Diab Rep, 16, 117, 10.1007/s11892-016-0795-6
Salamone, 2007, Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions, Physiol Behav, 91, 383, 10.1016/j.physbeh.2007.04.013
Lu, 2016, An introduction to the endogenous cannabinoid system, Biol Psychiatry, 79, 516, 10.1016/j.biopsych.2015.07.028
Schlosburg, 2010, Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system, Nat Neurosci, 13, 1113, 10.1038/nn.2616
Lowin, 2015, Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis, Arthritis Res Ther, 17, 226, 10.1186/s13075-015-0743-x
Pongratz, 2014, The sympathetic nervous response in inflammation, Arthritis Res Ther, 16, 504, 10.1186/s13075-014-0504-2
Capellino, 2010, Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target, Ann Rheum Dis, 69, 1853, 10.1136/ard.2009.119701
Russo, 2007, Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine, Chem Biodivers, 4, 1729, 10.1002/cbdv.200790150
Mucke, 2018, Cannabis-based medicines for chronic neuropathic pain in adults, Cochrane Database Syst Rev, 3, CD012182
Ware, 2005, The medicinal use of cannabis in the UK: results of a nationwide survey, Int J Clin Pract, 59, 291, 10.1111/j.1742-1241.2004.00271.x
Blake, 2006, Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis, Rheumatology (Oxford), 45, 50, 10.1093/rheumatology/kei183
Cox, 2007, The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor, Eur J Pharmacol, 570, 50, 10.1016/j.ejphar.2007.05.024
Petrovszki, 2012, The effects of peptide and lipid endocannabinoids on arthritic pain at the spinal level, Anesth Analg, 114, 1346, 10.1213/ANE.0b013e31824c4eeb
Klinger-Gratz, 2018, Acetaminophen relieves inflammatory pain through CB1 cannabinoid receptors in the rostral ventromedial medulla, J Neurosci, 38, 322, 10.1523/JNEUROSCI.1945-17.2017
Nugent, 2017, The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review, Ann Intern Med, 167, 319, 10.7326/M17-0155
De, 2008, Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8, J Pharmacol Exp Ther, 325, 1007, 10.1124/jpet.107.134809
Jeske, 2006, Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons, J Biol Chem, 281, 32879, 10.1074/jbc.M603220200
Ibrahim, 2005, CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids, Proc Natl Acad Sci U S A, 102, 3093, 10.1073/pnas.0409888102
Gao, 2016, Signaling mechanism of cannabinoid receptor-2 activation-induced beta-endorphin release, Mol Neurobiol, 53, 3616, 10.1007/s12035-015-9291-2
Yuill, 2017, Antinociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain, Mol Pain, 13, 1744806917728227, 10.1177/1744806917728227
Fox, 2001, The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain, Pain, 92, 91, 10.1016/S0304-3959(00)00474-7
Toth, 2009, Anandamide and the vanilloid receptor (TRPV1), Vitam Horm, 81, 389, 10.1016/S0083-6729(09)81015-7
Wang, 2014, Activation of CB1 inhibits NGF-induced sensitization of TRPV1 in adult mouse afferent neurons, Neuroscience, 277, 679, 10.1016/j.neuroscience.2014.07.041
Tsuji, 2010, Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents, Eur J Pharmacol, 627, 332, 10.1016/j.ejphar.2009.10.044
Ninomiya, 2017, Differences in the effects of four TRPV1 channel antagonists on lipopolysaccharide-induced cytokine production and COX-2 expression in murine macrophages, Biochem Biophys Res Commun, 484, 668, 10.1016/j.bbrc.2017.01.173
Starowicz, 2013, Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism, PLoS One, 8, e60040, 10.1371/journal.pone.0060040
Lizanecz, 2006, Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1, Mol Pharmacol, 69, 1015, 10.1124/mol.105.015644
Cichewicz, 2003, Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration, J Pharmacol Exp Ther, 304, 1010, 10.1124/jpet.102.045575
De Gregorio, 2019, Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain, Pain, 160, 136, 10.1097/j.pain.0000000000001386
Kaczocha, 2014, Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia, PLoS One, 9, e94200, 10.1371/journal.pone.0094200
Tanda, 2003, Cannabinoids: reward, dependence, and underlying neurochemical mechanisms – a review of recent preclinical data, Psychopharmacology (Berl), 169, 115, 10.1007/s00213-003-1485-z
Kangas, 2016, Comparisons of Delta9-tetrahydrocannabinol and anandamide on a battery of cognition-related behavior in nonhuman primates, J Pharmacol Exp Ther, 357, 125, 10.1124/jpet.115.228189
Wang, 2017, FAAH inhibition produces antidepressant-like efforts of mice to acute stress via synaptic long-term depression, Behav Brain Res, 324, 138, 10.1016/j.bbr.2017.01.054
Ahn, 2009, Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain, Chem Biol, 16, 411, 10.1016/j.chembiol.2009.02.013
Vaitheesvaran, 2012, Peripheral effects of FAAH deficiency on fuel and energy homeostasis: role of dysregulated lysine acetylation, PLoS One, 7, e33717, 10.1371/journal.pone.0033717